Shares of Seattle Genetics Inc. (NASDAQ:SGEN) have earned a consensus rating of “Hold” from the eighteen brokerages that are covering the stock. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $50.83.

Several brokerages recently commented on SGEN. TheStreet raised Seattle Genetics from a “sell” rating to a “hold” rating in a research note on Friday, October 28th. JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $43.00 price target on shares of Seattle Genetics in a research note on Monday, October 31st. HC Wainwright reaffirmed a “buy” rating on shares of Seattle Genetics in a research note on Sunday, October 30th. Leerink Swann reaffirmed an “outperform” rating and issued a $62.00 price target on shares of Seattle Genetics in a research note on Monday, October 24th. Finally, RBC Capital Markets reaffirmed an “outperform” rating and issued a $62.00 price target (up previously from $55.00) on shares of Seattle Genetics in a research note on Monday, October 10th.

In related news, Director Felix Baker acquired 1,030,629 shares of the company’s stock in a transaction that occurred on Thursday, November 3rd. The stock was acquired at an average price of $56.13 per share, for a total transaction of $57,849,205.77. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Clay B. Siegall sold 14,465 shares of the company’s stock in a transaction dated Monday, November 7th. The shares were sold at an average price of $58.43, for a total value of $845,189.95. The disclosure for this sale can be found here. 33.30% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the stock. Perigon Wealth Management LLC acquired a new stake in shares of Seattle Genetics during the second quarter valued at about $1,212,000. State Board of Administration of Florida Retirement System increased its stake in shares of Seattle Genetics by 17.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 179,627 shares of the company’s stock valued at $7,258,000 after buying an additional 26,935 shares during the period. Emerald Acquisition Ltd. acquired a new stake in shares of Seattle Genetics during the second quarter valued at about $16,220,000. Vanguard Group Inc. increased its stake in shares of Seattle Genetics by 2.6% in the second quarter. Vanguard Group Inc. now owns 7,110,502 shares of the company’s stock valued at $287,335,000 after buying an additional 178,403 shares during the period. Finally, Eqis Capital Management Inc. increased its stake in shares of Seattle Genetics by 4.6% in the second quarter. Eqis Capital Management Inc. now owns 38,087 shares of the company’s stock valued at $1,539,000 after buying an additional 1,658 shares during the period. Institutional investors and hedge funds own 96.57% of the company’s stock.

Seattle Genetics (NASDAQ:SGEN) traded up 0.67% on Friday, reaching $70.95. The company had a trading volume of 428,827 shares. The company’s market capitalization is $10.04 billion. The company’s 50 day moving average price is $58.62 and its 200-day moving average price is $48.06. Seattle Genetics has a 12 month low of $26.02 and a 12 month high of $75.36.

Seattle Genetics (NASDAQ:SGEN) last announced its quarterly earnings data on Thursday, October 27th. The company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.06. Seattle Genetics had a negative return on equity of 16.27% and a negative net margin of 27.03%. The company had revenue of $106.30 million for the quarter, compared to analyst estimates of $4.34 million. During the same quarter last year, the firm earned ($0.21) EPS. Seattle Genetics’s revenue for the quarter was up 26.4% compared to the same quarter last year. On average, equities analysts predict that Seattle Genetics will post ($0.95) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Seattle Genetics Inc. (SGEN) Given Consensus Recommendation of “Hold” by Analysts” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was copied illegally and reposted in violation of US and international trademark & copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2016/11/25/seattle-genetics-inc-sgen-given-consensus-recommendation-of-hold-by-analysts.html.

Seattle Genetics Company Profile

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE).

5 Day Chart for NASDAQ:SGEN

Receive News & Stock Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related stocks with our FREE daily email newsletter.